Net Income (Quarterly) Chart

View Net Income (Quarterly) for EPGNF.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Net Income (Quarterly) Chart
Start Trial

Historical Net Income (Quarterly) Data

View and export this data back to 2004. Start Trial.
Date Value
June 30, 2023 -2.866M
March 31, 2023 -5.999M
December 31, 2022 -6.636M
September 30, 2022 -1.570M
June 30, 2022 -1.385M
March 31, 2022 -2.981M
December 31, 2021 -1.985M
September 30, 2021 3.343M
June 30, 2021 -2.806M
March 31, 2021 -1.447M
December 31, 2020 -3.072M
September 30, 2020 -3.219M
June 30, 2020 -3.715M
March 31, 2020 -3.285M
December 31, 2019 -7.761M
September 30, 2019 -2.884M
June 30, 2019 -4.942M
March 31, 2019 -3.427M
December 31, 2018 -4.502M
September 30, 2018 -3.459M
June 30, 2018 -3.042M
March 31, 2018 -3.957M
December 31, 2017 -3.087M
September 30, 2017 -1.338M
June 30, 2017 -4.519M
Date Value
March 31, 2017 -2.526M
December 31, 2016 -1.299M
September 30, 2016 -2.609M
June 30, 2016 -3.720M
March 31, 2016 -4.768M
December 31, 2015 -1.042M
September 30, 2015 -2.680M
June 30, 2015 -2.720M
March 31, 2015 -3.557M
December 31, 2014 -3.682M
September 30, 2014 -2.440M
June 30, 2014 -2.500M
March 31, 2014 -3.069M
December 31, 2013 -2.966M
September 30, 2013 -2.486M
June 30, 2013 -2.14M
March 31, 2013 -2.266M
December 31, 2012 -3.605M
September 30, 2012 -4.617M
June 30, 2012 -4.340M
March 31, 2012 -3.065M
December 31, 2011 -6.545M
September 30, 2011 -6.797M
June 30, 2011 -4.333M
March 31, 2011 -3.955M

Net Income Definition

Represents net income for the period and date(s) requested in local currency by default.

Read full definition.

Net Income (Quarterly) Range, Past 5 Years

View Net Income (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Net Income (Quarterly) Benchmarks

View Net Income (Quarterly) Benchmarks
Start Trial
CureVac NV 319.28M
PAION AG --
Anbio Biotechnology --
Anika Therapeutics, Inc. 3.309M
Perspective Therapeutics, Inc. -26.98M

Net Income (Quarterly) Related Metrics